Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthriti

Clinical Infectious Diseases

Volumn 48, Issue 10, 2009, Pages 1364-1371

  McDonald, Jay R ^a,b   Zeringue, Angelique L ^a,b   Caplan, Liron ^a,d   Ranganathan, Prabha ^b   Xian, Hong ^a,b   Burroughs, Thomas E ^c   Fraser, Victoria J ^b   Cunningham, Fran ^e   Eisen, Seth A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e Veterans Affairs Pharmacy Benefits Management   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADALIMUMAB; AURANOFIN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FAMCICLOVIR; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; VALACICLOVIR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DRUG USE; FEMALE; HAZARD RATIO; HEALTH CARE SYSTEM; HERPES ZOSTER; HUMAN; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENINGITIS; MORBIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SURVIVAL; VALIDATION STUDY; VETERAN; AGE; AGED; INCIDENCE; MIDDLE AGED;

AGE FACTORS; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HERPES ZOSTER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VETERANS;

EID: 65549095761     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598331     Document Type: Article

References (32)

1. Wareham DW, Breuer J. Herpes zoster. BMJ 2007;334:1211-5.
2. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352:2266-7.
3. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004;4:26-33.
4. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and noninflammatory musculoskeletal disorders. Rheumatology 2006;45:1370-5.
5. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001;33:62-9.
6. Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immu- nocompromised patients: incidence, timing, and risk factors. Am J Med 2005;118:1416.
7. Schimpff S, Serpick A, Stoler B, et al. Varicella-zoster infection in patients with cancer. Ann Intern Med 1972;76:241-54.
8. Manzi S, Kuller LH, Kutzer J, et al. Herpes zoster in systemic lupus erythmatosus. J Rheumatol 1995;22:1254-8.
9. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-6.
10. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
11. Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions. JAMA 2004;292:2643-6.
12. Keystone EC. Safety of biologic therapies-an update. J Rheumatol Suppl 2005;74:8-12.
13. Baciu A, Stratton K, Burke SP, eds. The future ofdrug safety: promoting and protecting the health of the public. Washington DC: National Academies Press, 2007.
14. Singh JA, Holmgren AR, Noorbaloochi S. Accuracy of Veterans Administration databases for a diagnosis ofrheumatoid arthritis. Arthritis Rheum 2004;51:952-7.
15. American College ofRheumatologySubcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
16. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-a blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157- 63.
17. Elixhauser A, Steiner C, Harris DR, Coffey R. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
18. Kressin NR, Chang BH, Hendricks A, Kazis LE. Agreement between administrative data and patients' self-reports of race/ethnicity. Am J Public Health 2003;93:1734-9.
19. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-67.
20. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
21. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431-8.
22. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9.
23. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748-53.
24. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine 1982;61: 310-6.
25. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Gran- ulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
26. Gardam MA, Keystone EC, Menzies R, et al. Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
27. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects ofetanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007;12:9-15.
28. O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res 2005;40:1620-39.
29. Kashner TM. Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs. Med Care 1998;36:1324-36.
30. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
31. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271- 84.
32. Harpaz R, Ortega-Sanchez IR, Seward JF; Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008;57:1-30 (erratum: MMWR Recomm Rep 2008;57:779).